These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8996735)

  • 1. In vitro activity of sparfloxacin against Salmonella typhi.
    Qadri SM; Ueno Y; Almodovar E
    Chemotherapy; 1997; 43(1):6-9. PubMed ID: 8996735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Salmonella activity of CP-99,219, a novel azabicyclo-naphthridone fluoroquinolone.
    Qadri SM; Cunha BA; Ueno Y; Walters EA
    Chemotherapy; 1996; 42(6):439-42. PubMed ID: 8957578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
    Qadri SM; Ayub A; Ueno Y; Saldin H
    Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of enoxacin and other fluoroquinolones against multi-resistant strains of Salmonella typhi.
    Hannan A
    Curr Med Res Opin; 1992; 12(9):560-3. PubMed ID: 1316257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolones in Salmonella typhi infection.
    DuPont HL
    Drugs; 1993; 45 Suppl 3():119-24. PubMed ID: 7689442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae.
    Crump JA; Barrett TJ; Nelson JT; Angulo FJ
    Clin Infect Dis; 2003 Jul; 37(1):75-81. PubMed ID: 12830411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.
    Slinger R; Desjardins M; McCarthy AE; Ramotar K; Jessamine P; Guibord C; Toye B
    BMC Infect Dis; 2004 Sep; 4():36. PubMed ID: 15380025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of minimum inhibitory concentration of quinolones and third generation cephalosporins to Salmonella typhi isolates.
    Kumar R; Aneja KR; Roy P; Sharma M; Gupta R; Ram S
    Indian J Med Sci; 2002 Jan; 56(1):1-8. PubMed ID: 12508624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolones in the treatment of typhoid fever and the carrier state.
    Zavala Trujillo I; Quiroz C; Gutierrez MA; Arias J; Renteria M
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):334-41. PubMed ID: 1864294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.
    Booker BM; Smith PF; Forrest A; Bullock J; Kelchlin P; Bhavnani SM; Jones RN; Ambrose PG
    Antimicrob Agents Chemother; 2005 May; 49(5):1775-81. PubMed ID: 15855495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of Salmonella typhi to quinolones & cephalosporins.
    Bhat KG; Andrade AT; Karadesai SG; Hemashettar BM; Patil CS
    Indian J Med Res; 1998 Jun; 107():247-51. PubMed ID: 9701891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism of ciprofloxacin and trimethoprim against Salmonella enterica serovar typhi isolates showing reduced susceptibility to ciprofloxacin.
    Mandal S; Mandal MD; Pal NK
    Chemotherapy; 2004 Jun; 50(3):152-4. PubMed ID: 15272228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in-vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria.
    Sánchez-Carrillo C; Cotarelo M; Cercenado E; Vicente T; Blázquez R; Bouza E
    J Antimicrob Chemother; 1996 Jan; 37(1):151-4. PubMed ID: 8647757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The susceptibility of Salmonella sp. to various antibiotics].
    Willke A; Altay G; Erdem B
    Mikrobiyol Bul; 1988 Jan; 22(1):17-24. PubMed ID: 3273593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalidixic acid screening test in detection of decreased fluoroquinolone susceptibility in Salmonella typhi isolated from blood.
    Zafar A; Ibrahim NG; Ahsan T; Abbas Z; Zaidi A; Hasan R
    J Coll Physicians Surg Pak; 2005 Jul; 15(7):413-7. PubMed ID: 16197870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of Salmonella typhi to chloramphenicol, ampicillin and cotrimoxazole.
    Vongsthongsri U; Tharavanij S
    Southeast Asian J Trop Med Public Health; 1980 Jun; 11(2):256-61. PubMed ID: 6968979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India.
    Joshi S; Amarnath SK
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):308-10. PubMed ID: 16950486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.